Royal Bank of Canada’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,095
| Closed | -$2K | – | 7784 |
|
|
2024
Q1 | $2K | Sell |
1,095
-11,729
| -91% | -$17.4K | ﹤0.01% | 6735 |
|
|
2023
Q4 | $11K | Buy |
12,824
+3,633
| +40% | +$3.19K | ﹤0.01% | 6480 |
|
|
2023
Q3 | $10K | Buy |
9,191
+4,644
| +102% | +$9.61K | ﹤0.01% | 6432 |
|
|
2023
Q2 | $12K | Buy |
4,547
+1,057
| +30% | +$3.77K | ﹤0.01% | 6431 |
|
|
2023
Q1 | $14K | Sell |
3,490
-2,052
| -37% | -$9.48K | ﹤0.01% | 6182 |
|
|
2022
Q4 | $28K | Buy |
5,542
+2,347
| +73% | +$14.7K | ﹤0.01% | 6167 |
|
|
2022
Q3 | $41K | Buy |
3,195
+2,490
| +353% | +$37.7K | ﹤0.01% | 5835 |
|
|
2022
Q2 | $9K | Sell |
705
-1,609
| -70% | -$22.3K | ﹤0.01% | 6439 |
|
|
2022
Q1 | $36K | Sell |
2,314
-3,373
| -59% | -$52.6K | ﹤0.01% | 6295 |
|
|
2021
Q4 | $100K | Buy |
5,687
+2,792
| +96% | +$53.6K | ﹤0.01% | 5942 |
|
|
2021
Q3 | $60K | Buy |
2,895
+738
| +34% | +$16.2K | ﹤0.01% | 6056 |
|
|
2021
Q2 | $43K | Buy |
2,157
+507
| +31% | +$11.9K | ﹤0.01% | 6142 |
|
|
2021
Q1 | $48K | Buy |
+1,650
| New | +$46.2K | ﹤0.01% | 5916 |
|
|
2020
Q2 | – | Sell |
-933,959
| Closed | -$11.5M | – | 6996 |
|
|
2020
Q1 | $11.5M | Sell |
933,959
-1,716
| -0.2% | -$28K | 0.01% | 1229 |
|
|
2019
Q4 | $17.3M | Sell |
935,675
-272,692
| -23% | -$3.99M | 0.01% | 1244 |
|
|
2019
Q3 | $16.7M | Sell |
1,208,367
-66
| -0% | -$991 | 0.01% | 1197 |
|
|
2019
Q2 | $17.7M | Buy |
+1,208,433
| New | +$17.7M | 0.01% | 1187 |
|
Royal Bank of Canada's NGM Position: Q2 2024 in Review
Royal Bank of Canada sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 1,095 shares — an estimated $2K sold.
Royal Bank of Canada first reported a position in NGM in Q2 2019 and held it in 17 quarters. The position peaked at $17.7M in Q2 2019. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Royal Bank of Canada reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 1,095 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $2K.
- Royal Bank of Canada first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 17 quarters.
- Royal Bank of Canada's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $17.7M in Q2 2019.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.